Brandon Luber
Overview
Explore the profile of Brandon Luber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
4699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
O J, Jacene H, Luber B, Wang H, Huynh M, Leal J, et al.
J Nucl Med
. 2017 Apr;
58(9):1429-1434.
PMID: 28360211
The aim of this study was to assess the interobserver variability of quantitative F-FDG PET/CT parameters used in assessments of treatment response across multiple sites and readers. Paired pre- and...
12.
Gunn A, Sheth R, Luber B, Huynh M, Rachamreddy N, Kalva S
Cardiovasc Intervent Radiol
. 2016 Nov;
40(1):61-68.
PMID: 27834009
Purpose: The purpse of this study was to evaluate the ability of various radiologic response criteria to predict patient outcomes after trans-arterial chemo-embolization with drug-eluting beads (DEB-TACE) in patients with...
13.
Maughan B, Suzman D, Luber B, Wang H, Glavaris S, Hughes R, et al.
Cancer Chemother Pharmacol
. 2016 Nov;
78(6):1297-1304.
PMID: 27826729
Purpose: Hedgehog (Hh) pathway signaling has been implicated in prostate cancer tumorigenesis and metastatic development and may be upregulated even further in the castration-resistant state. We hypothesized that antagonism of...
14.
Maughan B, Luber B, Nadal R, Antonarakis E
Prostate
. 2016 Aug;
77(1):33-40.
PMID: 27527643
Background: There are no validated clinical decision tools to aid optimal treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). Frequently, abiraterone and enzalutamide are used prior to chemotherapy...
15.
Schweizer M, Wang H, Luber B, Nadal R, Spitz A, Rosen D, et al.
Prostate
. 2016 Jun;
76(13):1218-26.
PMID: 27338150
Background: We have previously documented a paradoxical anti-tumor effect when castration-resistant prostate cancer patients were treated with intermittent, high-dose testosterone (i.e., Bipolar Androgen Therapy; BAT). Because, an adaptive increase in...
16.
Rosenblum M, Luber B, Thompson R, Hanley D
Stat Med
. 2016 Apr;
35(21):3776-91.
PMID: 27076411
We propose a class of randomized trial designs aimed at gaining the advantages of wider generalizability and faster recruitment while mitigating the risks of including a population for which there...
17.
Wang J, Narang A, Sugar E, Luber B, Rosati L, Hsu C, et al.
Ann Surg Oncol
. 2015 Jul;
22 Suppl 3:S1100-6.
PMID: 26224402
Purpose: The role of adjuvant radiation for gallbladder carcinoma (GBC) is uncertain. We combine the experience of six National Cancer Institute-designated cancer centers to explore the impact of adjuvant radiation...
18.
Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al.
JAMA Oncol
. 2015 Jul;
1(5):582-91.
PMID: 26181238
Importance: We previously showed that detection of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer (CRPC) was associated with primary resistance...
19.
Lipson E, Sharfman W, Chen S, McMiller T, Pritchard T, Salas J, et al.
J Transl Med
. 2015 Jul;
13:214.
PMID: 26143264
Background: Limited adjuvant treatment options exist for patients with high-risk surgically resected melanoma. This first-in-human study investigated the safety, tolerability and immunologic correlates of Melanoma GVAX, a lethally irradiated granulocyte-macrophage...
20.
Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J, et al.
N Engl J Med
. 2014 Sep;
371(11):1028-38.
PMID: 25184630
Background: The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We...